A detailed history of Bellevue Group Ag transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 15,700 shares of RYTM stock, worth $933,993. This represents 0.01% of its overall portfolio holdings.

Number of Shares
15,700
Previous 13,000 20.77%
Holding current value
$933,993
Previous $533,000 54.22%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.81 - $55.0 $110,187 - $148,500
2,700 Added 20.77%
15,700 $822,000
Q2 2024

Aug 14, 2024

BUY
$35.41 - $44.37 $17,705 - $22,185
500 Added 4.0%
13,000 $533,000
Q1 2024

May 15, 2024

SELL
$39.12 - $52.44 $796,835 - $1.07 Million
-20,369 Reduced 61.97%
12,500 $541,000
Q4 2023

Feb 14, 2024

SELL
$21.39 - $49.64 $864,819 - $2.01 Million
-40,431 Reduced 55.16%
32,869 $1.51 Million
Q3 2023

Nov 14, 2023

BUY
$15.81 - $27.8 $1.16 Million - $2.04 Million
73,300 New
73,300 $1.68 Million

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.31B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.